Mode
Text Size
Log in / Sign up
Phase 3 Completed N=444 Randomized Treatment

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Source: ClinicalTrials.gov NCT02131064 ↗
Enrolled (actual)
444
Serious AEs
22.6%
Results posted
Jun 2017
Primary outcomePrimary: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples — 56.1; 44.4 Percentage of Participants — p=0.0126
◆ Published Evidence
Highly cited
526citations · ~66 / year
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
The Lancet. Oncology · 2018 · Open access · Likely link

Summary

This is a randomized, multicenter, open-label, two-arm study in treatment-naive participants with operable, locally advanced, or inflammatory, centrally-assessed HER2-positive early breast cancer (EBC) whose primary tumors were greater than or equal to (>/=) 2 centimeters (cm). The study was designed to evaluate the efficacy and safety of trastuzumab emtansine + pertuzumab (experimental arm; T-DM1 + P) versus chemotherapy, trastuzumab + pertuzumab (control arm; TCH + P). The study comprised a neoadjuvant treatment period, followed by surgery, and an adjuvant treatment period. Treatment can be stopped due to disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination.

Linked Publications (3)

  • Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    The Lancet. Oncology · 2018 · 526 citations · Open access · Likely link
  • Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019 · 248 citations · Open access · Likely link
  • Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
    Breast cancer research : BCR · 2023 · 43 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples
56.1; 44.4 0.0126 sig
SECONDARY
Overall Survival
97.6; 97.0 0.7557
SECONDARY
Percentage of Participants Who Received Breast-Conserving Surgery (BCS)
52.6; 41.7 0.0228 sig
SECONDARY
Event-Free Survival
94.21; 85.28 0.0027 sig
SECONDARY
Invasive Disease-free Survival (IDFS)
91.99; 93.04
SECONDARY
Percentage of Participants by Response for Neuropathy Single Item
78.7; 81.2; 9.5; 9.4; 0; 0
SECONDARY
Percentage of Participants by Response for Skin Problem Single Items
71.9; 72.6; 14.9; 16.1; 0; 0
SECONDARY
Percentage of Participants With a Clinically Meaningful Deterioration in Global Health Status (GHS)/Quality of Life (QoL) Score
69.9; 45.4
SECONDARY
Time to Clinically Meaningful Deterioration in GHS/QoL Score
3.02; 4.63 0.0001 sig
SECONDARY
Time to Clinically Meaningful Deterioration in Function Subscale
2.79; 4.86; 2.79; 4.44; 3.42; 4.44
SECONDARY
Maximum Observed Serum Concentration (Cmax) of Trastuzumab
167; 148; 159; 181
SECONDARY
Cmax of Trastuzumab Emtansine and Total Trastuzumab
80.4; 71.7; 79.1; 79.1; 70.4; 73.1
SECONDARY
Minimum Observed Serum Concentration (Cmin) of Trastuzumab
45.8; 21.8
SECONDARY
Cmin of Trastuzumab Emtansine and Total Trastuzumab
3.04; 12.3; 4.09; 8.70
SECONDARY
Plasma N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maytansine (DM1) Concentrations
4.64; 4.73; 4.49; 5.15
SECONDARY
Serum Levels of Plasma DM1-Containing Catabolites Concentrations (in ng/mL) (Nonreducible Thioether Linker [MCC]-DM1 and Lysine [Lys]-MCC-DM1)
8.18; NA; 8.22; NA; 7.98; NA
SECONDARY
Percentage of Participants With ATA to Trastuzumab
11; 2.6; 5.4; 5.0
SECONDARY
Percentage of Participants by Response for Hair Loss Single Item
81.4; 87.4; 7.7; 4.0; 0; 0
SECONDARY
Percentage of Participants With Selected Adverse Events (AEs)
14.2; 39.0; 0.9; 4.9; 4.6; 1.3
SECONDARY
Percentage of Participants With a Clinically Meaningful Deterioration in Function Subscales
59.1; 42.4; 72.5; 40.0; 76.7; 47.8
SECONDARY
Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to TDM-1
5.5; 7.5; 11.7; 13.1
SECONDARY
Percentage of Participants With a Clinically Meaningful Increase in Symptom Subscales
61.1; 47.8; 91.2; 40.5; 89.7; 75.1

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed invasive breast cancer with a primary tumor size of greater than (>) 2 cm
  • HER2-positive breast cancer
  • Participants with multifocal tumors (more than one tumor confined to the same quadrant as the primary tumor) are eligible provided all discrete lesions are sampled and centrally confirmed as HER2 positive
  • Stage at presentation: cT2-cT4, cN0-cN3, cM0, according to American Joint Committee on Cancer (AJCC) staging system
  • Known hormone receptor status of the primary tumor
  • Participant agreement to undergo mastectomy or breast-conserving surgery after neoadjuvant therapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Baseline Left Ventricular Ejection Fraction (LVEF) >/= 55 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA)
  • Effective contraception as defined by protocol

Exclusion Criteria

  • Stage IV (metastatic) breast cancer
  • Participants who have received prior anti-cancer therapy for breast cancer except those participants with a history of breast lobular carcinoma in situ (LCIS) that was surgically managed or ductal carcinoma in situ (DCIS) treated exclusively with mastectomy. In case of prior history of LCIS/DCIS, >5 years must have passed from surgery until diagnosis of current breast cancer
  • Participants with multicentric (multiple tumors involving more than 1 quadrant) or bilateral breast cancer
  • Participants who have undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes
  • Axillary lymph node dissection or positive sentinel lymph node prior to start of neoadjuvant therapy
  • History of concurrent or previously non-breast malignancies except for appropriately treated (1) non-melanoma skin cancer and (2) in situ carcinomas, including cervix, colon, and skin. A participant with previous invasive non-breast cancer is eligible provided he/she has been disease-free >/= 5 years
  • Treatment with any investigational drug within 28 days prior to randomization
  • Current National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0
  • Any significant concurrent medical or surgical conditions or findings that would jeopardize the participant's safety or ability to complete the study
  • Current pregnancy or breastfeeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02131064) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search